The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology
about
Amphiregulin mediates progesterone-induced mammary ductal development during pubertyPostpartum remodeling, lactation, and breast cancer risk: summary of a National Cancer Institute-sponsored workshopScribble modulates the MAPK/Fra1 pathway to disrupt luminal and ductal integrity and suppress tumour formation in the mammary glandRestoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and PreventionHER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast CancerCell type-specific activation of AKT and ERK signaling pathways by small negatively-charged magnetic nanoparticlesCD147, CD44, and the epidermal growth factor receptor (EGFR) signaling pathway cooperate to regulate breast epithelial cell invasiveness.The Huntington disease protein accelerates breast tumour development and metastasis through ErbB2/HER2 signalling.Host matrix modulation by tumor exosomes promotes motility and invasiveness.AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer modelsFunctional analysis implicating the SNP rs61552325 in ERBB2 as an effector for androgen-insensitive prostate cancer cell invasion.Differential role of psoriasin (S100A7) in estrogen receptor α positive and negative breast cancer cells occur through actin remodelingGenetic ablation of the fatty acid-binding protein FABP5 suppresses HER2-induced mammary tumorigenesis.ErbB2 receptor immunoreactivity in prostate cancer: relationship to the androgen receptor, disease severity at diagnosis and disease outcome.Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer patients.Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib.Mammary glands exhibit molecular laterality and undergo left-right asymmetric ductal epithelial growth in MMTV-cNeu mice.Inhibition of triple-negative and Herceptin-resistant breast cancer cell proliferation and migration by Annexin A2 antibodies.Identification of anti-ErbB2 dual variable domain immunoglobulin (DVD-Ig™) proteins with unique activities.Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6PTPRG suppresses tumor growth and invasion via inhibition of Akt signaling in nasopharyngeal carcinoma.Activated platelets rescue apoptotic cells via paracrine activation of EGFR and DNA-dependent protein kinase.Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancerIntegrin α6β4 Promotes Autocrine Epidermal Growth Factor Receptor (EGFR) Signaling to Stimulate Migration and Invasion toward Hepatocyte Growth Factor (HGF).R(h)oads to microvesiclesTriptolide Transcriptionally Represses HER2 in Ovarian Cancer Cells by Targeting NF-κBPathways to breast cancer recurrence.Endocrine resistance in breast cancer: from cellular signaling pathways to epigenetic mechanisms.Kisspeptin/KISS1R System in Breast CancerInhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells.Cancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma.Role of epidermal growth factor receptor in breast cancer.Prolactin activates ERα in the absence of ligand in female mammary development and carcinogenesis in vivoHER2/HER3 regulates extracellular acidification and cell migration through MTK1 (MEKK4).G(i)α proteins exhibit functional differences in the activation of ERK1/2, Akt and mTORC1 by growth factors in normal and breast cancer cells.Interleukin-6 expression contributes to lapatinib resistance through maintenance of stemness property in HER2-positive breast cancer cells.TACE-dependent TGFα shedding drives triple-negative breast cancer cell invasion.Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells.The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy.
P2860
Q21195190-72751753-4BDA-4696-9786-39D13C1ABD06Q26823516-DAD41EF0-A916-4A64-8B54-A3B37CEDEA1EQ27315980-D3DA894E-FFCF-47FE-957D-A58DCE44427DQ28067145-3FED1982-BDED-4140-B9D9-283301B0EC44Q28237833-90ED5CCE-4214-4742-87C4-B50C517F6E15Q28391111-AD263A82-1546-453A-80D4-F6FB608EDFDCQ30431290-1E3E13B3-4E46-40D8-A984-CADCFFAD4D1DQ30535295-1712E881-EA6C-41F3-BF3D-2F098EC75BAFQ30541999-E2AACEDF-FCCA-49F4-929E-898C4CDD5E79Q33770856-E725C4AA-8145-4735-B7A5-34CD00F193BEQ33779668-F48F2A55-1F33-4E02-B68E-64AA3504F41FQ33804642-6BB0A3EE-87EB-421D-9BD5-A8086D0972D0Q33850093-762F525A-D86B-45BB-ADA4-4F547ACBFE9EQ34172262-1C53F4FF-E23F-4F6F-A299-F71BCB58F603Q34240076-768D19FF-2306-4D3C-94BA-C11702AA1C66Q34572719-89451496-459E-487F-BCFE-37F360D37DC9Q34664059-416C3A4C-79A9-442A-BB10-C4434687498AQ34687047-8024CFFA-8B82-4A6D-A68B-B09D86E322ECQ35168105-ED54995F-80C9-4533-85CE-94523A9912C9Q35625440-193E592D-1E2C-492F-A86A-F5ABD35C6B71Q35955342-3B1BEB04-1616-42D2-BA00-23FA67549710Q35966249-231CBA33-BBF2-4EF9-9BAC-4B78A1F99E7BQ36092726-2C616F41-C650-4F9E-B0D0-065B08772F79Q36283930-1C451F33-1B66-4CBA-A36E-EE2225916D10Q36463007-17FF9BAB-B7C5-42B2-BCA3-F33A66D7B7F0Q36528524-55F47409-1678-4403-B74D-F176CB45E162Q36702139-95F82D30-E634-4CF9-9F6A-1FB99723FA8FQ36846329-5973E2D8-C13E-49B3-93B1-01BFE8150EB5Q37249506-303E0DA7-DDE4-44BC-BC49-55479213ACABQ37294562-C4E44998-5E7D-4E63-A312-7FAB5F6735C6Q37316834-B0126DD1-FB23-46D2-9358-427D6AD71780Q37320346-3BADE667-0CB9-4176-A301-9B93AABAD09EQ37331101-F9AE1B1C-A3C6-48B2-BE53-B8E54F2DBB83Q37407344-F69A193E-6652-4F30-ACB3-22F29BD63926Q37607405-152E68CF-B238-46D5-A660-DFC0CEDCC632Q37641777-00F0BFB7-F5B7-414A-9816-EA1859543DFBQ37663864-CFB48DCB-51B8-4AAE-9CE8-7EB519EAE620Q37690272-CBA1FD46-4907-4C07-B4D3-159A8D50C154Q37701488-46AD047C-62A9-4314-AE6D-CDB935ED08EDQ38192017-32FB1EC1-6446-4F3A-83E1-E73454C2AEAA
P2860
The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The epidermal growth factor re ...... l and malignant breast biology
@ast
The epidermal growth factor re ...... l and malignant breast biology
@en
The epidermal growth factor re ...... l and malignant breast biology
@nl
type
label
The epidermal growth factor re ...... l and malignant breast biology
@ast
The epidermal growth factor re ...... l and malignant breast biology
@en
The epidermal growth factor re ...... l and malignant breast biology
@nl
prefLabel
The epidermal growth factor re ...... l and malignant breast biology
@ast
The epidermal growth factor re ...... l and malignant breast biology
@en
The epidermal growth factor re ...... l and malignant breast biology
@nl
P3181
P356
P1476
The epidermal growth factor re ...... l and malignant breast biology
@en
P2093
Suzanne A. Eccles
P304
P3181
P356
10.1387/IJDB.113396SE
P407
P577
2011-01-01T00:00:00Z